Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) shares saw unusually-high trading volume on Friday . Approximately 4,025,141 shares traded hands during trading, an increase of 23% from the previous session’s volume of 3,267,425 shares.The stock last traded at $3.54 and had previously closed at $3.83.

SGYP has been the topic of a number of research analyst reports. Rodman & Renshaw dropped their price target on Synergy Pharmaceuticals from $16.00 to $15.00 and set a “buy” rating on the stock in a research report on Monday, May 9th. Roth Capital reaffirmed a “buy” rating and set a $6.50 price target on shares of Synergy Pharmaceuticals in a research report on Thursday, May 26th. Zacks Investment Research raised Synergy Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 price target on the stock in a research report on Monday, May 16th. Canaccord Genuity reaffirmed a “buy” rating and set a $13.00 price target on shares of Synergy Pharmaceuticals in a research report on Monday, May 23rd. Finally, BTIG Research reissued a “buy” rating and issued a $11.00 target price on shares of Synergy Pharmaceuticals in a research report on Tuesday, April 19th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $10.37.

The company’s market capitalization is $648.99 million. The firm’s 50-day moving average price is $3.81 and its 200-day moving average price is $3.60.

Synergy Pharmaceuticals (NASDAQ:SGYP) last posted its quarterly earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by $0.28. Analysts predict that Synergy Pharmaceuticals Inc. will post ($1.01) EPS for the current year.

A number of hedge funds and institutional investors have recently bought and sold shares of the company. Morgan Stanley increased its position in Synergy Pharmaceuticals by 6.8% in the fourth quarter. Morgan Stanley now owns 423,520 shares of the biopharmaceutical company’s stock worth $2,401,000 after buying an additional 27,037 shares during the period. Oxford Asset Management purchased a new position in Synergy Pharmaceuticals during the fourth quarter worth $1,102,000. Finally, California State Teachers Retirement System increased its position in Synergy Pharmaceuticals by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 185,372 shares of the biopharmaceutical company’s stock worth $1,051,000 after buying an additional 3,251 shares during the period.

Synergy Pharmaceuticals Inc (Synergy) is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s GI platform includes two lead product candidates: plecanatide and dolcanatide. It is engaged in the discovery, research and development involving uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.